The Prevalence of Men With National Institutes of Health Category IV Prostatitis and Association With Serum Prostate Specific Antigen

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Feb 2003The Prevalence of Men With National Institutes of Health Category IV Prostatitis and Association With Serum Prostate Specific Antigen BRETT S. CARVER, CALEB B. BOZEMAN, B.J. WILLIAMS, and DENNIS D. VENABLE BRETT S. CARVERBRETT S. CARVER , CALEB B. BOZEMANCALEB B. BOZEMAN , B.J. WILLIAMSB.J. WILLIAMS , and DENNIS D. VENABLEDENNIS D. VENABLE View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)63959-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated the prevalence and relationship of serum prostate specific antigen (PSA) levels in a screening population of men diagnosed with National Institutes of Health (NIH) category IV prostatitis. Materials and Methods: In September of 2001, 300 men were randomly selected from our prostate cancer awareness screening program to be evaluated for NIH category IV prostatitis. After informed consent was obtained all patients completed the NIH prostate cancer awareness survey and had a serum sample obtained for PSA before examination. Expressed prostatic secretions were obtained from 227 of the 300 participants. Patients were classified according to findings on examination of the expressed prostatic secretions. The records were entered into our data base and subsequently reviewed. Results: The prevalence of NIH category IV prostatitis was 32.2% in our population of men. Patient age, American Urological Association symptom scores and clinical prostate gland size did not differ between men with or without evidence of prostatitis on expressed prostatic secretion examination. Men with NIH category IV prostatitis had a mean serum PSA level of 2.3 which was significantly higher (p <0.0004) than those without prostatitis (mean PSA 1.4). Conclusions: These data suggest that NIH category IV prostatitis is fairly prevalent (32.2%) among men in the general population who present for prostate cancer screening and appears to contribute to increased serum PSA levels in some men. References 1 : Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology1999; 54: 229. Google Scholar 2 : Questionnaire survey of urologists and primary care physicians' diagnostics and treatment practices for prostatitis. Urology1997; 50: 543. Google Scholar 3 : How common is prostatitis? A national survey of physician visits. J Urol1998; 159: 1224. Link, Google Scholar 4 : Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology1998; 51: 578. Google Scholar 5 : Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol1995; 154: 407. Link, Google Scholar 6 : Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate1994; 25: 91. Google Scholar 7 : Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J Urol2000; 164: 1550. Link, Google Scholar 8 : Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol2002; 167: 1723. Link, Google Scholar 9 : Prostatitis. Med Clin North Am1991; 75: 405. Google Scholar 10 : Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol2002; 167: 1363. Google Scholar 11 : Comparison of serum prostate-specific antigen levels and PSA density in African-American, white, and Hispanic men without prostate cancer. Urology1998; 51: 300. Google Scholar 12 : Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst1997; 89: 134. Google Scholar 13 : Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. J Urol1999; 162: 2014. Link, Google Scholar From the Department of Urology, Louisiana State University Health Sciences Center, Shreveport, Louisiana© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byTekin A, Yuksel A, Tekin S, Gumrukcu G, Aslan A and Sengor F (2018) Post-Prostatic Massage Examination for Prediction of Asymptomatic Prostatitis in Needle Biopsies: A Prospective StudyJournal of Urology, VOL. 182, NO. 2, (564-569), Online publication date: 1-Aug-2009.SCHAEFFER A, WU S, TENNENBERG A and KAHN J (2018) TREATMENT OF CHRONIC BACTERIAL PROSTATITIS WITH LEVOFLOXACIN AND CIPROFLOXACIN LOWERS SERUM PROSTATE SPECIFIC ANTIGENJournal of Urology, VOL. 174, NO. 1, (161-164), Online publication date: 1-Jul-2005.PLATZ E and De MARZO A (2018) Epidemiology of Inflammation and Prostate CancerJournal of Urology, VOL. 171, NO. 2S, (S36-S40), Online publication date: 1-Feb-2004.NELSON W, DE MARZO A, DeWEESE T and ISAACS W (2018) THE ROLE OF INFLAMMATION IN THE PATHOGENESIS OF PROSTATE CANCERJournal of Urology, VOL. 172, NO. 5S, (S6-S12), Online publication date: 1-Nov-2004. Volume 169Issue 2February 2003Page: 589-591 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.Keywordsprostate-specific antigen, mass screeningprostatic neoplasmsNational Institutes of Health (U.S.)prostatitisMetricsAuthor Information BRETT S. CARVER More articles by this author CALEB B. BOZEMAN More articles by this author B.J. WILLIAMS More articles by this author DENNIS D. VENABLE More articles by this author Expand All Advertisement PDF downloadLoading ...